Synthetic biology provides insight into natural gene-network dynamics and enables assembly of engineered transcription circuitries for production of difficult-to-access therapeutic molecules. In Mycobacterium tuberculosis EthR binds to a specific operator (OethR) thereby repressing ethA and preventing EthA-catalyzed conversion of the prodrug ethionamide, which increases the resistance of the pathogen to this last-line-of-defense treatment. We have designed a synthetic mammalian gene circuit that senses the EthR-OethR interaction in human cells and produces a quantitative reporter gene expression readout. Challenging of the synthetic network with compounds of a rationally designed chemical library revealed 2-phenylethyl-butyrate as a nontoxic substance that abolished EthR's repressor function inside human cells, in mice, and within M. tuberculosis where it triggered derepression of ethA and increased the sensitivity of this pathogen to ethionamide. The discovery of antituberculosis compounds by using synthetic mammalian gene circuits may establish a new line of defense against multidrug-resistant M. tuberculosis.
U
p to 9 million people contract tuberculosis every year and 50 million people are presently infected with Mycobacterium tuberculosis resistant to both first-line drugs isoniazid and rifampicin (1) [World Health Organization (WHO), fact sheet no. 104, March 2007] . Ethionamide, a structural analogue of isoniazid, is currently the last line of defense in the treatment of multidrugresistant tuberculosis (MDR-TB). During 35 years of its clinical use, ethionamide has fortunately elicited little cross-resistance with isoniazid because both prodrugs have to be activated by different mycobacterial enzymes to develop their antimicrobial activity (2) . Ethionamide is activated by the Baeyer-Villiger monooxygenase EthA, which converts the prodrug into an antimycobacterial nicotinamide adenine dinucleotide derivative (3, 4) . Because ethA is repressed by EthR (5), ethionamide-based tuberculosis therapy is often unsuccessful even when prescribed at high hepatotoxic doses (6) . Therefore, compounds preventing EthR from binding to the ethA promoter could increase the sensitivity of multidrug-resistant M. tuberculosis to ethionamide and make tuberculosis treatment safer, more efficient, and affordable. Crystallography-based structural analysis implied that hexadecylocanoate copurifying with EthR could abolish EthR's operator-binding capacity (7) . However, hexadecyloctanoate turned out to be too hydrophobic to confirm this hypothesis in any cell/microbial culture system suggesting that it remains a nontrivial challenge to discover bioavailable EthRbinding compounds. Because M. tuberculosis is an intracellular pathogen, EthR inhibitors do not only have to specifically target the bacterial repressor, but also need to reach the cytosol without eliciting any cytotoxic effect. Therefore, integrated screening approaches assessing specificity, bioavailability, and cytotoxicity in a single assay are expected to rapidly reveal valid drug candidates. Although synthetic mammalian gene networks designed so far, including epigenetic toggle switches (8) , hysteresis networks (9), time-delay circuits (10) , and synthetic ecosystems (11) , have resulted in important information on the dynamics of physiologic control systems, the EthR-based gene circuit pioneers a direction with a more practical purpose: providing a generic screening platform to discover drug candidates with the potential to efficiently kill M. tuberculosis, the causative agent of one of the most devastating human diseases.
Results
Design of an EthR-Based Synthetic Mammalian Gene Circuit. Structural analysis (7, 12) classifying EthR as a TetR/CamR family repressor suggested the existence of compounds that could modulate the affinity of EthR for its O ethR operator (13, 14) . Adopting a synthetic biology approach we have designed a gene network whose topology enabled detection of EthR-binding molecules inside human cells, thereby scoring for noncytotoxic and bioavailable compounds accessing the pathogenic habitat of M. tuberculosis (Fig. 1a) . The gene circuit consists of a synthetic transactivator, EthR, fused to the VP16 transactivation domain of Herpes simplex (pWW489, P SV40 -EthR-VP16-pA), which induces SEAP (human placental secreted alkaline phosphatase) expression in human embryonic kidney cells (HEK-293) after binding to a chimeric promoter containing the EthR-specific operator (O ethR ) 5Ј of a minimal Drosophila heat shock protein 70 promoter (P hsp90min ; pWW491, O ethR -P hsp70min -SEAP-pA) (8.2 Ϯ 0.8 units/liter; background level of pWW491, 0.4 Ϯ 0.1 units/liter) (Fig. 1a) . Cell-permeable EthR-interacting compounds were expected to release EthR-VP16 from O ethR -P hsp70min , thereby repressing SEAP production to basal levels (Fig. 1a) . Interestingly, hexadecyloctanoate (10 mM), identified in crystallography studies to compromise EthR's DNA-binding capacity (7), failed to decrease SEAP expression in HEK-293 cells containing pWW489 and pWW491 (data not shown), which is probably because of its highly lipophilic structure (ClogP ϭ 11.29). Therefore, it remains a nontrivial challenge to discover bioavailable EthR-binding compounds as they must be sufficiently lipophilic to fit into the hydrophobic tunnel of EthR (7) while being hydrophilic enough to reach therapeutic levels in the bloodstream and inside infected cells.
Discovery of Compounds Affecting the DNA-Binding Affinity of EthR.
Capitalizing on crystallography data describing EthR's smallmolecule binding site as ''hydrophobic tunnel-like cavity fitting a lipophilic ligand'' (7, 12) and on the observation that repressors are often feedback-controlled by the products of their target gene (15, 16) , we have synthesized a library of hydrophilic esters (ClogP Ͻ 4), a substance class, which is the main product of EthA-catalyzed Baeyer-Villiger oxidation (Fig. 1b) . When HEK-293 populations containing the EthR-based gene circuit (Fig. 1a) were exposed to 0-3.2 mM individual library components, only benzylacetate, 3-phenylpropyl-propionate, 2-phenylethyl-butyrate, and 4-phenyl-2-butanone [a ketone class control (7)] induced a significant decrease in SEAP expression, suggesting that these compounds may trigger the release of EthR from O ethR (Fig. 1c) . However, because 3-phenylpropyl-propionate and 4-phenyl-2-butanone were also reducing SEAP levels of HEK-ET-SEAP cells transgenic for constitutive SEAP expression (Fig. 1c) , these substances were considered cytotoxic at EthR-releasing concentrations [SEAP production and viability of HEK-ET-SEAP cells were shown to correlate; supporting information (SI) Fig. S1 ]. Therefore, only benzylacetate (IC 50 ϭ 1 mM) and 2-phenylethyl-butyrate (IC 50 ϭ 0.5 mM) were used for further studies (Fig. 1c) .
Validation of EthR-Modulating Compounds in Bacteria and in Vitro.
When exposing Escherichia coli engineered for P ethR -driven GFP expression to benzylacetate and 2-phenylethyl-butyrate concentrations used for the aforementioned experiments with mammalian cells, dose-dependent GFP expression could be observed, indicating that these compounds were also able to trigger release of EthR from O ethR in prokaryotes ( Fig. 2 a and b; see Fig. S2 for expression constructs and experimental setup). Similar to mammalian cells, hexadecyloctanoate was unable to modulate EthR's P ethR -binding affinity in E. coli at concentrations up to 10 mM (data not shown). Benzylacetate efficiently released EthR from its operator but did so only at elevated concentrations (10 mM) that are known to be mutagenic and likely incompatible with future therapeutic use (Material Safety Data Sheet, Sigma). We have therefore focused on 2-phenylethyl-butyrate and further characterized the adjustable EthR-O ethR release capacity of this licensed food additive in a cell-free ELISA system (Fig. 2c) : Hexahistidine-tagged EthR (EthR-His 6 ) was allowed to bind to agarose beads containing immobilized O ethR in the presence of increasing concentrations of 2-phenylethyl-butyrate and O ethRinteracting EthR-His 6 was quantified after a washing step by using a His 6 -specific horseradish peroxidase-coupled antibody and a standard assay system (Fig. 2c) . The inverse correlation of 2-phenylethyl-butyrate and O ethR -bound EthR indicates that this compound is able to induce release of EthR from its operator. The specificity of 2-phenylethyl-butyrate's EthR-releasing capacity was confirmed by an identical control experiment with an unrelated repressor-operator interaction (Fig. S3) . The optical density at 600 nm (OD 600) after the growth period is indicated as well. As a control, E. coli BL21(DE3) transformed with pWW856 alone were used in parallel. (b) Effect of 2-phenylethyl-butyrate in E. coli. Experimental setup as described in a. (c) Impact of 2-phenylethyl-butyrate on the interaction between EthR and O ethR in vitro. Biotinylated operator OethR (O) immobilized on streptavidin-agarose beads (SA-Agarose) was incubated in the presence or absence of 2-phenylethyl-butyrate at the indicated concentrations in a cell lysate of E. coli BL21(DE3) transformed with pWW862 (P T7-ethR-his6-term) for production of hexahistidine-tagged EthR (R-his6). After washing, his6-tagged EthR was detected by a monoclonal anti-his6 antibody coupled to horseradish peroxidase (HRP), resulting in the conversion of 3,3Ј,5,5Ј-tetramethylbenzidine (TMB) to a colored formazane. As negative controls, nonrecombinant cell lysate was used (neg).
bacterial nicotinamide adenine dinucleotide derivative (3, 17) . EthR-mediated repression of ethA transcription requires rather high clinical doses of ethionamide [up to 1g/day (6, 18)], which is associated with severe side effects including neurotoxicity (19) and fatal hepatotoxicity (6), yet is often still insufficient to reach minimum inhibitory levels in the bloodstream (20) . Therefore, 2-phenylethyl-butyrate-triggered dissociation of EthR from the ethA promoter resulting in derepression of ethA, which was confirmed by quantitative RT-PCR of ethA transcripts (2.93 Ϯ 0.04-and 9.7 Ϯ 1.7-fold increase in the presence of 0.5 and 2 mM 2-phenylethyl-butyrate, respectively), may increase the sensitivity of Mycobacterium to ethionamide-based therapy. Growth of M. bovis bacillus Calmette-Guérin and M. tuberculosis H37Rv in the presence of subinhibitory ethionamide concentrations (0.25 and 0.5 g/ml), which are easily reached by therapeutic doses [c max (250 mg oral) ϭ 2 g/ml; t 1/2 ϭ 2 h (18)] was dosedependently inhibited by 0.5 and 2 mM 2-phenylethyl-butyrate (Fig. 3) . Because 2-phenylethyl-butyrate alone did not show any growth inhibitory effect, we suggest that it acted synergistically with ethionamide to kill the pathogen (Fig. 3) . 4-Phenyl-2-butanone, which was previously suggested to neutralize EthR, was found to be cytotoxic (Fig. 1c and Fig. S1 ) and did not act synergistically with ethionamide to kill M. bovis at concentrations that were higher than the ones at which 2-phenylethyl-butyrate was effective (Fig. S5) .
Discussion
Synthetic gene circuits have dramatically increased progress on gene-function relationships in the postgenomic era (8) (9) (10) (11) (21) (22) (23) (24) (25) . They also continue to provide the key parts for synthetic biologists to decipher natural gene network dynamics (8) (9) (10) and to reprogram cellular function for production of important precursor drugs (23) . We have engineered a synthetic gene network in human cells for screening of functional antimicrobial agents with precise target specificity, undetectable cytotoxicity, and the capacity to reach the cytosol to eliminate intracellular pathogens. The network setup is generic so that it can, in principle, be adapted to essential transcription regulators of other pathogens. With the integration of EthR (4), which controls the resistance of M. tuberculosis to ethionamide, into a synthetic mammalian gene network we have been able to identify the licensed food additive 2-phenylethyl-butyrate as a potent inhibitor of EthR in M. tuberculosis, as well as in vivo, which dramatically increases the sensitivity of this pathogen to the last-line-of-defense drug ethionamide and potentially to other ethA-dependent compounds (26) . Therefore, 2-phenylethylbutyrate could set up an efficient and safe line of defense against multidrug-resistant tuberculosis.
Materials and Methods
Vector Design. pWW489 (PSV40-ethR-vp16-pA) was constructed by PCRmediated amplification of ethR from genomic M. bovis DNA by using oligonucleotides OWW400 (5Ј-gcatccatatgaattccaccatgaccacctccgcggcca-3Ј) and OWW401 (5Ј-cgatcgcgcgcggctgtacgcggagcggttctcgccgtaaatgc-3Ј) followed by restriction and ligation (EcoRI/BssHII) into pWW35 (27) . pWW491 (O ethR-P hsp70min-SEAP-pA) was obtained by direct cloning of a synthetic OethR sequence (5Ј-gacgtcgatccacgctatcaacgtaatgtcgaggccgtcaacgagatgtcgacactatcgacacgtagcctgcagg-3Ј) (AatII/SbfI) into pMF172 (27) . pWW488 (P T7-ethR-vp16-his 6) was constructed by PCR-mediated amplification of ethR-vp16 from pWW489 by using oligonucleotides OWW400 and OWW60 (5Ј-gctctagagcaagcttttaatggtgatggtgatgatgcccaccgtactgtcaattccaag-3Ј) followed by cloning (NdeI/HindIII) into pRSETmod (28) . pWW856 (P ethR-gfp-pA) was constructed in three steps: (i) gfp was PCR-amplified from pLEGFP-N1 (Clontech) by using oligonucleotides OWW848 (5Ј-ggcttgaattcaaaggagatataccatggtgagcaagggcgag-3Ј) and OWW849 (5Ј-ggctttctagacaaaaaacccctcaagacccgtttagaggccccaaggggttatgctagttacttgtacagctcgtccatgccg-3Ј) and cloned (EcoRI/XbaI) into pWW56 (27) (pWW854). (ii) A synthetic O ethR sequence was directly cloned (HindIII/EcoRI) into pWW854 (pWW855). (iii) P ethRgfp was excised (BamHI/StuI) from pWW855 and ligated (BamHI/ScaI) into pACYC177 (NEB) (pWW856). pWW862 (P T7-ethR-his6) was assembled by annealing oligonucleotides OWW479 (5Ј-cgcgcatcatcatcatcatcattaagcggccgca-3Ј) and OWW480 (5Јagcttgcggccgcttaatgatgatgatgatgatg-3Ј) and cloning the double-stranded DNA BssHII/HindIII into pWW488. pWW871 (5ЈLTR-⌿ ϩ -ethRvp16-P PGK-neo R -3ЈLTR) was designed by cloning ethR-vp16 of pWW489 (EcoRI/ BamHI) into pMSCVneo (Clontech). pWW35 (P SV40-E-vp16-pA), pWW37 (ETR-P hCMVmin-seap-pA) and pWW313 (PT7-E-his6-pA) have been described (28) .
Cell Culture. Human embryonic kidney cells (HEK-293, American Type Culture Collection CRL-1573) were cultivated in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% FCS (Pan Biotech GmbH, catalog no. 3302, lot P231902) and 1% of a penicillin/streptomycin solution (Sigma, catalog no. 4458). Cells were transfected by using standard calcium phosphate procedures (29) and retroviral particles were produced according to the manufacturer's protocol (Clontech). EthRHEK, transgenic for constitutive EthR-VP16 expression, was constructed by transducing HEK-293 with pWW871-derived retroviral particles followed by selection in DMEM containing 200 g/ml neomycin and single-cell cloning. Cotransfection of EthRHEK with pWW491 and pPUR (Clontech), subsequent selection in 200 g/ml neomycin, 1 g/ml puromycin followed by single-cell cloning resulted in EthRHEK-SEAP. The cell line HEK-ET-SEAP, transgenic for constitutive SEAP expression, was described in ref. 27 .
SEAP was quantified in cell culture supernatants by using a p-nitrophenylphosphate-based assay (30) and in mouse serum by employing a commercial chemiluminescence test (Roche Applied Science, catalog no. 11779842001). The impact of chemicals on the viability of human cells was assessed by using the WST-1 cell proliferation assay according the to manufacturer's protocol (Roche Applied Science, catalog no. 05015944001).
Chemicals. Pentyl-acetate, methyl-phenylacetate, 2-phenylethyl-acetate, 4-phenyl-2-butanone (all Fluka) and 2-phenylethyl-butyrate (Sigma) were commercially obtained. Methyl-hexanoate was obtained by reacting hexanoic acid with thionylchloride in methanol. Butyl-propionate, 2-phenylethyl-propionate, 2-phenylethyl-isopentanoate, and 3-phenylpropyl-propionate were prepared by reacting the corresponding alcohol with the acid chloride in dichloromethane by using triethylamine as a base. Hexadecyloctanoate and benzylacetate were synthesized from the bromide and the acid with K2CO3 as the base in dimethylformamide. All esters were purified either by column chromatography (silica, ethylacetate/hexane) or distillation. ClogP was determined by using Chemdraw Ultra 10.0 (CambridgeSoft). Erythromycin (Sigma, catalog no. E5389) was used as a 1,000ϫ stock solution of 5 mg/ml in ethanol. Ethionamide was purchased from Sigma (catalog no. E6005) and prepared as 200ϫ stock solution in DMSO.
FACS Analysis. E. coli BL21(DE3) (Invitrogen), transformed with pWW488 and pWW856 or pWW856 alone, were grown overnight in Luria Bertani (LB) media containing 100 g/ml ampicillin and 30 g/ml kanamycin (for pWW856-transformed cells only). Then, 150 l of E. coli suspension (OD600 1.3) was added to 2 ml of fresh LB media containing antibiotics and 1 mM isopropyl ␤-D-thiogalactoside (IPTG) where indicated. After growth for 5.5 h at 37°C, 500 l of the suspension was transferred to a new tube and centrifuged for 3min at 800 ϫ g. The pellet was washed twice with 1 ml of PBS and resuspended in 2 ml of PBS for FACS analysis (Ͼ10,000 cells per sample), which was performed on a Cytomics FC500 (Beckman Coulter) with 405 nm used for excitation and 510 nm for emission. FACS gates are shown in Fig. S2 ELISA. The EthR-his 6-specific ELISA was performed as previously described for the E-his 6-based ELISA (28) For quantitative analysis of ethA transcripts, M. tuberculosis H37Rv were treated at midlog phase with DMSO (40-fold dilution) or 2-phenylethylbutyrate (0.5 or 2 mM) for 24 h at 37°C, harvested by centrifugation (4,400 ϫ g, 10min, 4°C) and total RNA was extracted by using the RiboPure-Bacteria Kit (Ambion, catalog no. AM1925) according to the manufacturer's protocol. Total RNA was reverse transcribed (25°C, 10 min; 48°C, 30min; 95°C, 5min) by using TaqMan reverse transcription reagents (Applied Biosystems, catalog no. N8080234) and ethA-specific cDNA was quantified on an Applied Biosystems 7500 real-time PCR device by using the following ethA-specific primers: forward primer, 5Ј-cgatcacgacgatgttcttagc-3Ј; reverse primer, 5Ј-tcgggccgatcatccat-3Ј; probe labeled with 5ЈFAM and 3ЈTAMRA, 5Ј-FAM-cgtagtcgaggtcctcgggccagt-TAMRA-3Ј. All samples were standardized by using the M. tuberculosis sigA gene [Rv2703 (32) ] and the following sigA-specific primers: forward primer, 5Ј-ccgatgacgacgaggagatc-3Ј; reverse primer, 5Ј-ggcctccgactcgtcttca-3Ј; probe labeled with 5ЈFAM and 3ЈTAMRA dyes, 5Ј-FAMaaggacaaggcctccggtgatttcg-TAMRA-3Ј. Characterization of the screening system. E. coli BL21(DE3), transformed with pWW488 and pWW856, were grown in the presence or absence of IPTG (to induce EthR-VP16 production) for 5.5 h before FACS analysis. As controls, wild-type (wt) bacteria or bacteria transformed with pWW856 alone were used. The cell populations were grouped into three categories according to their fluorescence levels (gates a, b, and c). S3 . Specificity of the 2-phenylethyl-butyrate activity. To exclude that 2-phenylethyl-butyrate undiscriminatingly modulates protein-DNA interactions the macrolide-dependent repressor-operator configuration was challenged with this compound in an identical ELISA set-up as shown in Fig. 2c . The E-ETR interaction was insensitive to 2-phenylethyl-butyrate and could exclusively be abolished in the presence of erythromycin (EM, 5 g/ml). 
